Results 51 to 60 of about 5,546 (214)

Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST2 and SST5 homo- and hetero-dimer formation

open access: yesFrontiers in Endocrinology, 2022
The process of GPCR dimerization can have profound effects on GPCR activation, signaling, and intracellular trafficking. Somatostatin receptors (SSTs) are class A GPCRs abundantly expressed in pituitary tumors where they represent the main ...
Donatella Treppiedi   +13 more
doaj   +1 more source

IGF-I influences everolimus activity in medullary thyroid carcinoma [PDF]

open access: yes, 2015
Context: Medullary thyroid carcinoma (MTC) is a rare tumor originating from thyroid parafollicular C cells. It has been previously demonstrated that insulin-like growth factor I (IGF-I) protects MTC from the effects of antiproliferative drugs. Everolimus,
degli Uberti, Ettore C.   +9 more
core   +1 more source

Toward Precision Medicine: Gene Therapy Applications in the Management of Uveal Melanoma

open access: yesCancer Reports, Volume 8, Issue 12, December 2025.
ABSTRACT Background Uveal melanoma (UM) is the prevailing malignant tumor that develops within the eye in adults, and it has a bleak outlook because of the few treatment choices available and the high likelihood of returning after treatment. Currently, surgical intervention, radiation therapy, and a combination of both modalities are available ...
Alireza Azani   +13 more
wiley   +1 more source

Efficacy and safety of pasireotide-LAR for the treatment of refractory bleeding due to gastrointestinal angiodysplasias: results of the ANGIOPAS multicenter phase II noncomparative prospective double-blinded randomized study

open access: yesTherapeutic Advances in Gastroenterology, 2018
Background: Gastrointestinal angiodysplasias (GIADs) could be responsible for recurrent bleeding and severe anemia. Somatostatin analogs could reduce transfusion requirements in these patients but no randomized controlled study is available.
Robert Benamouzig   +17 more
doaj   +1 more source

Loss of efficacy of pasireotide after its re-administration: is there a reason why?

open access: yesRare Tumors, 2016
Pasireotide is a recently approved medical treatment for persistent or recurrent Cushing’s disease (CD). However, an escape from the initial successful response has not yet been described.
Stylianos Mandanas   +4 more
doaj   +1 more source

Pasireotide versus octreotide in acromegaly: A head-to-head superiority study [PDF]

open access: yes, 2014
Context: Biochemical control reduces morbidity and increases life expectancy in patients with acromegaly. With current medical therapies, including the gold standard octreotide long-acting-release (LAR), many patients do not achieve biochemical control.
Bronstein, MD   +14 more
core   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: G protein‐coupled receptors

open access: yesBritish Journal of Pharmacology, Volume 182, Issue S1, Page S24-S151, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander   +206 more
wiley   +1 more source

Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours [PDF]

open access: yes, 2019
Pancreatic Neuroendocrine Neoplasms comprise a group of rare tumours with special biology, an often indolent behaviour and particular diagnostic and therapeutic requirements.
Almar E.   +123 more
core   +4 more sources

Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts’ consensus statement

open access: yesFrontiers in Endocrinology
Pasireotide is a somatostatin analogue for the treatment of acromegaly, a chronic condition caused by excess growth hormone. Despite the therapeutic benefits of pasireotide as a second-line treatment for inadequately controlled acromegaly, a major ...
Sylvère Störmann   +8 more
doaj   +1 more source

A transplantable phosphorylation probe for direct assessment of G protein-coupled receptor activation. [PDF]

open access: yesPLoS ONE, 2012
The newly developed multireceptor somatostatin analogs pasireotide (SOM230), octreotide and somatoprim (DG3173) have primarily been characterized according to their binding profiles.
Andrea Kliewer   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy